@article{oai:dwcla.repo.nii.ac.jp:00001736,
 author = {松元, 加奈 and Matsumoto, Kana and 仲村, 弥栄子 and Nakamura, Yaeko and 佐藤, 敦夫 and Sato, Atsuo and 朝倉, 庄志 and Asakura, Shoji and 森田, 邦彦 and Morita, Kunihiko},
 journal = {同志社女子大學學術研究年報, Doshisha Women's College of Liberal Arts annual reports of studies},
 month = {Dec},
 note = {application/pdf, AN0016561X-20190930-127, A patient was given generic itraconazole (ITCZ) tablet, brand-name-ITCZ capsule, ITCZ oral solution and ITCZ injection to treat pulmonary aspergillosis. We monitored concentrations of ITCZ and its active metabolite hydroxy-ITCZ (OH-ITCZ) in plasma and lung tissues. During administration of the generic product (400 mg/day), trough plasma concentrations of ITCZ and OH-ITCZ were 76 ng/mL and 126 ng/mL, respectively. After administration of the brand-name product (200 mg/day), they increased to 229 ng/mL and 540 ng/mL, respectively. ITCZ and OH-ITCZ concentrations/dosage ratios were 6.1 and 8.4 times higher by switching to the brand-name product, respectively. It was suggested that there may be a difference in pharmacokinetics between the brand-name ITCZ and the generic. Also, we determined ITCZ and OH-ITCZ concentrations infected and uninfected tissues of resected lung simultaneously. The ITCZ concentration in the infected lesion of the lung was approximately 2.3 times higher than that in plasma and 1.6 times higher than in uninfected lung tissue. The OH-ITCZ concentration in the infected lesion was higher than ITCZ in the same region. It was considered that the high concentrations of ITCZ and its metabolite at infected lesion were due to their high affinities with ergosterol in fungal membrane., 研究ノート},
 pages = {127--132},
 title = {肺アスペルギルス症患者におけるイトラコナゾールおよび},
 volume = {68},
 year = {2017},
 yomi = {マツモト, カナ and ナカムラ, ヤエコ and サトウ, アツオ and アサクラ, ショウジ and モリタ, クニヒコ}
}